Protara Therapeutics Inc
TARA3.085USD
+0.025+0.82%
交易中 （美东）报价延迟15分钟
119.01M总市值
亏损市盈率 TTM
关于 Protara Therapeutics Inc 公司
Protara Therapeutics, Inc. 是一家临床阶段的生物技术公司，致力于为癌症和罕见疾病患者开发变革性疗法。该公司的产品组合包括其主要候选药物 TARA-002，这是一种正在开发的用于治疗非肌层浸润性膀胱癌 (NMIBC) 和淋巴畸形 (LM) 的试验性细胞疗法。该公司正在对 TARA-002 进行一项正在进行的 II 期试验，该试验针对对卡介苗 (BCG) 治疗无反应或未接受过治疗的原位癌 (CIS) NMIBC 患者，以及一项 II 期试验，该试验针对患有 LM 的儿科患者。此外，该公司正在开发静脉注射氯化胆碱，这是一种试验性磷脂底物替代品，适用于接受肠外营养且无法通过口服或肠内途径满足胆碱需求的患者。
公司简介
公司代码TARA
公司名称Protara Therapeutics Inc
上市日期Oct 22, 2014
CEOMr. Jesse Shefferman
员工数量28
证券类型Ordinary Share
年结日Oct 22
公司地址345 Park Avenue South
城市NEW YORK
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编10010
电话16468440337
网址https://protaratx.com/
公司代码TARA
上市日期Oct 22, 2014
CEOMr. Jesse Shefferman
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Luke M. Beshar, CPA
Mr. Luke M. Beshar, CPA
Independent Chairman of the Board
Independent Chairman of the Board
198.00K
--
Dr. Jacqueline Zummo, Ph.D.
Dr. Jacqueline Zummo, Ph.D.
Chief Scientific Operations Officer
Chief Scientific Operations Officer
52.40K
-9.50%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
51.00K
+64.52%
William Conkling
William Conkling
Chief Commercial Officer
Chief Commercial Officer
50.00K
--
Ms. Hannah Fry
Ms. Hannah Fry
Controller
Controller
36.81K
+23.38%
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Independent Director
Independent Director
33.00K
--
Mr. Gregory P. Sargen
Mr. Gregory P. Sargen
Independent Director
Independent Director
31.00K
--
Dr. Michael Edward (Mike) Solomon, Ph.D.
Dr. Michael Edward (Mike) Solomon, Ph.D.
Independent Director
Independent Director
26.50K
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Chief Financial Officer
Chief Financial Officer
4.27K
-79.09%
Ms. Justine O'Malley
Ms. Justine O'Malley
Investor Relations
Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Luke M. Beshar, CPA
Mr. Luke M. Beshar, CPA
Independent Chairman of the Board
Independent Chairman of the Board
198.00K
--
Dr. Jacqueline Zummo, Ph.D.
Dr. Jacqueline Zummo, Ph.D.
Chief Scientific Operations Officer
Chief Scientific Operations Officer
52.40K
-9.50%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
51.00K
+64.52%
William Conkling
William Conkling
Chief Commercial Officer
Chief Commercial Officer
50.00K
--
Ms. Hannah Fry
Ms. Hannah Fry
Controller
Controller
36.81K
+23.38%
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Independent Director
Independent Director
33.00K
--
收入明细
FY2019
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
9.82%
RA Capital Management, LP
8.81%
Blackstone Alternative Asset Management, L.P.
4.52%
Opaleye Management Inc.
4.48%
Velan Capital Investment Management LP
4.32%
Other
68.04%
持股股东
持股股东
占比
Janus Henderson Investors
9.82%
RA Capital Management, LP
8.81%
Blackstone Alternative Asset Management, L.P.
4.52%
Opaleye Management Inc.
4.48%
Velan Capital Investment Management LP
4.32%
Other
68.04%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
21.94%
Hedge Fund
20.37%
Investment Advisor
15.94%
Venture Capital
13.71%
Individual Investor
2.88%
Research Firm
2.69%
Pension Fund
0.19%
Bank and Trust
0.10%
Other
22.18%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
113
30.02M
77.80%
-5.36M
2025Q1
109
30.14M
79.11%
-5.49M
2024Q4
103
31.00M
91.11%
+17.03M
2024Q3
78
11.90M
57.00%
-1.22M
2024Q2
78
11.87M
56.87%
+435.17K
2024Q1
73
5.94M
51.57%
-1.39M
2023Q4
74
5.63M
49.24%
-1.76M
2023Q3
82
6.95M
61.22%
-1.14M
2023Q2
92
7.24M
64.00%
-2.26M
2023Q1
120
7.75M
68.57%
-3.28M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
3.79M
9.82%
--
--
Mar 31, 2025
RA Capital Management, LP
3.40M
8.81%
--
--
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
1.74M
4.52%
+64.04K
+3.81%
Mar 31, 2025
Opaleye Management Inc.
1.73M
4.48%
-95.00K
-5.21%
Mar 31, 2025
Velan Capital Investment Management LP
1.67M
4.32%
+88.80K
+5.62%
Mar 31, 2025
The Vanguard Group, Inc.
1.60M
4.15%
+243.34K
+17.90%
Mar 31, 2025
Sio Capital Management, LLC
1.51M
3.92%
+76.80K
+5.34%
Mar 31, 2025
Integral Health Asset Management, LLC
1.40M
3.63%
--
--
Mar 31, 2025
Acorn Capital Advisors, LLC
1.28M
3.32%
--
--
Mar 31, 2025
StemPoint Capital LP
1.19M
3.09%
+858.18K
+258.18%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.01%
ProShares UltraPro Russell2000
占比0%
Global X Russell 2000 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
